Cancer care in Jordan

Abdel‐Razeq, Hikmat; Attiga, Fadwa; Mansour, Asem

doi:10.1016/j.hemonc.2015.02.001

Cited by 139 publications

(146 citation statements)

References 5 publications

Supporting

Mentioning

142

Contrasting

Order By: Relevance

“…The survey population includes urban areas of two northern governorates of Jordan so may not be generalizable to other settings. Nevertheless, more than 80% of Jordan's population is urban, 90% live either in or north of Amman, and the Zarqa and Amman governorates are among the most populous areas of the country with hospitals serving diverse patient populations . Data are also gathered from hospitals where CB collection is more logistically feasible as they are in geographic proximity to the CB storage options located in the Amman governorate.…”

Section: Discussionmentioning

confidence: 99%

Public–private divide: cultural and social factors in women's attitudes toward cord blood banking in Jordan

2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Public–private divide: cultural and social factors in women's attitudes toward cord blood banking in Jordan

2018

View full text Add to dashboard Cite

show abstract

“…The disparities in CRC survival between Eastern Mediterranean countries may be attributed to several factors including differences in socioeconomic status, stage at diagnosis, treatment, physician characteristics, and hospital factors. The better survival in Jordan compared with other countries in the region might be explained by the fact that cancer care in Jordan is more advanced in comparison to most neighboring countries, and the country hosts many local and western-trained physicians who can deliver various cancer treatment modalities [21]. Currently, the King Hussein Cancer Foundation and Center (KHCC) treats around 60% of cancer cases in Jordan.…”

Section: Discussionmentioning

confidence: 99%

Colorectal Cancer in Jordan: Survival Rate and Its Related Factors

Sharkas

Arqoub

Khader

et al. 2017

Journal of Oncology

View full text Add to dashboard Cite

Objectives. To estimate the survival rate of colorectal cancer (CRC) and determine its predictors among Jordanian patients who were diagnosed in the period of 2005–2010. Methods. This study was based on Jordan cancer registry. All CRC cases that were registered in cancer registry during 2005–2010 were analyzed using the survival analysis. The last date for follow-up was 1st Oct 2016. Results. A total of 3005 patients with CRC were registered during 2005–2010. The overall 5-year and 10-year survival rates for patients with CRC were 58.2% and 51.8%, respectively. The 5-year survival rate decreased significantly from 60.4% for the age <50 years to 49.3% for the age ≥70 years (p < 0.005). The 5-year survival rate was 72.1% for the localized stage, 53.8% for the regional stage, and 22.6% for the distant metastasis. In the multivariate analysis, the only factors that were significantly associated with survival were age, grade, stage, and location of tumor. Conclusions. The overall 5-year and ten-year survival rates for CRC were 58.2% and 51.8%, respectively. Increased age, poor differentiation, advanced cancer stage, and right-sided cancers were associated with lower survival rates. Screening strategies are needed for early detection of colon adenomas and colorectal cancer in Jordan.

show abstract

“…In Jordan, colorectal cancer accounts for 10.3% and 8.9% of cancer-related deaths in males and females, respectively [2]. Surgical resection of the primary tumor and involved lymph nodes is the primary treatment for early-stage localized tumors.…”

Section: Introductionmentioning

confidence: 99%

The Hdac Inhibitor Sodium Phenylbutyrate Enhances the Cytotoxicity Induced by 5-Fluorouracil, Oxaliplatin, and Irinotecan in Colorectal Cancer Cell Lines

Al-Keilani

Alsmadi

2018

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: The main objective of this study was to evaluate the ability of sodium phenylbutyrate (NaPB) to enhance the cytotoxicity of 5-fluorouracil, oxaliplatin, and irinotecan against colorectal cancer cell lines expressing wild-type and mutant p53. Methods:The antiproliferative effect of NaPB alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using the MTT cell proliferation assay. IC50 values were calculated using Compusyn Software 1.0 (Combosyn Inc.). Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50Results: NaPB inhibited the growth of HCT-116 and HT-29 cell lines in a dose-dependent manner (IC s. For each two pairs of experiments, student's t-test was used for analysis. In combination studies, one-way ANOVA test; Tukey post-hoc testing was performed using R 3.3.2 software. P-value<0.05 was considered significant. 50Conclusion: NaPB enhanced the cytotoxicity of conventional chemotherapy against colorectal cancer cell lines harboring wild-type or mutant p53. Thus NaPB is a promising potential adjuvant chemotherapy in colorectal cancer. s 4.7 mmol, and 10.1 mmol, respectively). HT-29 cell lines (mutant p53) were more sensitive to NaPB at low concentrations (<4 mmol). Moreover, the addition of NaPB to HCT-116 and HT-29 with 5-fluorouracil, oxaliplatin, or irinotecan synergistically induced the antiproliferative effect (R>1.6, p-value<0.05).

show abstract

Cancer care in Jordan

Cited by 139 publications

References 5 publications

Public–private divide: cultural and social factors in women's attitudes toward cord blood banking in Jordan

Public–private divide: cultural and social factors in women's attitudes toward cord blood banking in Jordan

Colorectal Cancer in Jordan: Survival Rate and Its Related Factors

The Hdac Inhibitor Sodium Phenylbutyrate Enhances the Cytotoxicity Induced by 5-Fluorouracil, Oxaliplatin, and Irinotecan in Colorectal Cancer Cell Lines

Contact Info

Product

Resources

About